123 related articles for article (PubMed ID: 21680987)
1. A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Basile J
Postgrad Med; 2011 Jul; 123(4):38-45. PubMed ID: 21680987
[TBL] [Abstract][Full Text] [Related]
2. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
3. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Hsia DS; Grove O; Cefalu WT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):73-79. PubMed ID: 27898586
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
Vallon V; Sharma K
Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):425-31. PubMed ID: 20539226
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors: not every drug has the same effect.
Staruschenko A
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
[No Abstract] [Full Text] [Related]
6. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.
Abdul-Ghani MA; DeFronzo RA
J Intern Med; 2014 Oct; 276(4):352-63. PubMed ID: 24690096
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?
de Boer IH; Kahn SE
J Am Soc Nephrol; 2017 Jan; 28(1):7-10. PubMed ID: 27539605
[No Abstract] [Full Text] [Related]
8. Understanding the kidneys' role in blood glucose regulation.
Triplitt CL
Am J Manag Care; 2012 Jan; 18(1 Suppl):S11-6. PubMed ID: 22559853
[TBL] [Abstract][Full Text] [Related]
9. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
10. [Contribution of the kidney to glucose homeostasis].
Segura J; Ruilope LM
Med Clin (Barc); 2013 Sep; 141 Suppl 2():26-30. PubMed ID: 24444521
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors in the treatment of type 2 diabetes.
Hasan FM; Alsahli M; Gerich JE
Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
[TBL] [Abstract][Full Text] [Related]
13. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin in patients with type 2 diabetes mellitus.
Filippatos TD; Liberopoulos EN; Elisaf MS
Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
[TBL] [Abstract][Full Text] [Related]
15. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Powell J; Miller SA; Taylor JR
South Med J; 2015 Feb; 108(2):82-90. PubMed ID: 25688892
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
Vivian EM
Drugs Context; 2014; 3():212264. PubMed ID: 25598831
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
Moses RG; Colagiuri S; Pollock C
Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
[TBL] [Abstract][Full Text] [Related]
20. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.
Rosenstock J; Hansen L; Zee P; Li Y; Cook W; Hirshberg B; Iqbal N
Diabetes Care; 2015 Mar; 38(3):376-83. PubMed ID: 25352655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
